INNO-LIA® HCV Score

Optimal coverage of immunodominant HCV epitopes using unique and specific antigens 

Line immunoassay for the detection of antibodies to human hepatitis C virus in human serum and plasma. It is intended for use as a supplementary test on human serum or plasma specimens found to be reactive in an anti-HCV screening procedure.

The INNO-LIA HCV Score assay utilizes well-defined antigens derived from HCV immunodominant proteins from the core region, the E2 hypervariable region (HVR), the NS3 helicase region and the NS4A, NS4B and NS5A regions. The antigens used are either recombinant proteins or synthetic peptides, highly purified, and fixed on a nylon membrane.

    INNO-LIA® HCV Score

    Product number 80538

    20 Tests
    CE marked (IVDR)
    Please contact your local Fujirebio representative for the availability of this product in your country.

    Click here to navigate

    • Details
    • Conditions of sale
    • Citations
    • Documentation
    • Related products
    • Details

      Features & Benefits

      • Low follow-up rate
      • Low indeterminate rate
      • High sensitivity in BBI panels
      • Short and overnight procedures
      • Color-coded reagents
      • Ready-to-use reagents
      • Four control lines to monitor 1) non-specific reactivity, 2) sample addition,  3) and 4) color development steps
      • Fully automated strip processing possible using TENDIGO™, Auto-LIA™ 48, AutoBlot 3000(H) or Roboblot®
      • Objective, automated reading and interpretation of the strips possible using LiRAS® for Infectious Diseases
    • Conditions of sale

      To read the end user conditions of sale for this product please visit our Resource center.

    • Citations

      The BIOZ badges associated with Fujirebio products include peer-reviewed citations derived from scientific studies using Fujirebio products. Please note that the peer-reviewed citations do not reflect the regulatory status of Fujirebio products. Users should refer to the specific product documentation and any (clinical) claims made therein in order to ensure compliant use. For each country or geographic region, users must verify the related regulatory status of the Fujirebio product.